Insider Richard Miller reports 7.8% Corvus (CRVS) ownership in 13G/A

Rhea-AI Filing Summary

Corvus Pharmaceuticals, Inc. insider ownership is detailed in an amended Schedule 13G filing. As of December 31, 2025, Dr. Richard A. Miller is reported as the beneficial owner of 6,085,922 shares of common stock, or 7.8% of the class, based on 74,681,872 shares outstanding as of November 4, 2025.

Dr. Miller’s position includes 1,136,707 shares held directly, 1,188,103 shares held through the Miller-Horning Family Trust, and 3,761,112 shares underlying stock options that are vested or vest within 60 days of December 31, 2025. The Miller-Horning Family Trust and Dr. Sandra J. Horning each beneficially own 1,188,103 shares, representing 1.6% of the common stock.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 10)

Corvus Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

221015100

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 221015100

1

Names of Reporting Persons

Richard A. Miller

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,897,819.00
6	Shared Voting Power 1,188,103.00
7	Sole Dispositive Power 4,897,819.00
8	Shared Dispositive Power 1,188,103.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,085,922.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.8 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 221015100

1

Names of Reporting Persons

Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,188,103.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,188,103.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,188,103.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.6 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 221015100

1

Names of Reporting Persons

Sandra J. Horning

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,188,103.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,188,103.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,188,103.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.6 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Corvus Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 901 Gateway Boulevard, Third Floor, South San Francisco, CA 94080
Item 2.
(a)	Name of person filing: Richard A. Miller ("Dr. Miller") Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the "Miller-Horning Trust") Sandra J. Horning ("Dr. Horning," and collectively with Dr. Miller and the Miller-Horning Trust, the "Reporting Persons")
(b)	Address or principal business office or, if none, residence: c/o Corvus Pharmaceuticals, Inc., 901 Gateway Boulevard, Third Floor, South San Francisco, CA 94080
(c)	Citizenship: Dr. Miller is a U.S. citizen. The Miller-Horning Trust is organized under the laws of the State of California. Dr. Horning is a U.S. citizen.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 221015100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2025, based upon 74,681,872 shares of Common Stock outstanding as of November 4, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2025. All percentages assume the exercise of stock options held directly by each of the Reporting Persons, as applicable. Dr. Miller is the beneficial owner of 6,085,922 shares of Common Stock, which consists of (i) 1,136,707 shares of Common Stock held directly by Dr. Miller, (ii) 1,188,103 shares of Common Stock directly held by the Miller-Horning Trust, over which Dr. Miller and Dr. Horning share voting, investment and dispositive power, and (iii) 3,761,112 shares of Common Stock underlying stock options that are vested or will vest within 60 days of December 31, 2025. Each of the Miller-Horning Trust and Dr. Horning is the beneficial owner of 1,188,103 shares of Common Stock.
(b)	Percent of class: Dr. Miller - 7.8% Miller-Horning Trust - 1.6% Dr. Horning - 1.6%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Dr. Miller - 4,897,819 Miller-Horning Trust - 0 Dr. Horning - 0
	(ii) Shared power to vote or to direct the vote: Dr. Miller - 1,188,103 Miller-Horning Trust - 1,188,103 Dr. Horning - 1,188,103
	(iii) Sole power to dispose or to direct the disposition of: Dr. Miller - 4,897,819 Miller-Horning Trust - 0 Dr. Horning - 0
	(iv) Shared power to dispose or to direct the disposition of: Dr. Miller - 1,188,103 Miller-Horning Trust - 1,188,103 Dr. Horning - 1,188,103
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Richard A. Miller

Signature:	/s/ Richard A. Miller
Name/Title:	Richard A. Miller
Date:	02/13/2026

Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985

Signature:	/s/ Richard A. Miller
Name/Title:	Richard A. Miller, Trustee
Date:	02/13/2026

Sandra J. Horning

Signature:	/s/ Richard A. Miller
Name/Title:	Richard A. Miller, Authorized Signatory
Date:	02/13/2026

FAQ

How many Corvus Pharmaceuticals (CRVS) shares does Richard A. Miller beneficially own?

Richard A. Miller beneficially owns 6,085,922 shares of Corvus Pharmaceuticals common stock, representing 7.8% of the class. This total includes directly held shares, trust-held shares, and 3,761,112 option shares that are vested or vest within 60 days of December 31, 2025.

What percentage of Corvus Pharmaceuticals (CRVS) is held by the Miller-Horning Family Trust?

The Miller-Horning Family Trust beneficially owns 1,188,103 shares of Corvus Pharmaceuticals common stock, equal to 1.6% of the outstanding shares. Richard A. Miller and Sandra J. Horning, as trustees, share voting and dispositive power over these trust-held shares.

What is Sandra J. Horning’s ownership stake in Corvus Pharmaceuticals (CRVS)?

Sandra J. Horning is reported as the beneficial owner of 1,188,103 shares of Corvus Pharmaceuticals common stock, representing 1.6% of the class. Her beneficial ownership arises through shared voting and dispositive power over shares held by the Miller-Horning Family Trust.

How were the ownership percentages for CRVS calculated in this Schedule 13G/A?

Ownership percentages are based on 74,681,872 shares of Corvus common stock outstanding as of November 4, 2025, as disclosed in a Form 10-Q. The filing also assumes exercise of stock options that are vested or will vest within 60 days of December 31, 2025.

What portion of Richard A. Miller’s CRVS stake consists of stock options?

Of Richard A. Miller’s 6,085,922 beneficially owned shares, 3,761,112 shares are underlying stock options that are vested or will vest within 60 days of December 31, 2025. These option shares are included when calculating his reported ownership percentage.

Does this Corvus Pharmaceuticals (CRVS) Schedule 13G/A indicate group ownership?

The filing identifies three reporting persons: Richard A. Miller, the Miller-Horning Family Trust, and Sandra J. Horning. It provides separate ownership and voting power figures for each, and the standard Schedule 13G group-related items are each marked “Not Applicable.”